This is starting to smell like a huge winner... Cathie caught the bottom there as she added to ARK Investment Management is a leading shareholder in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) with 19 million shares worth more than $624 million. I am the Bottom Guy! Just love them. ASCO is always the time to do stuff... We need a ASCo play & a bottom play and here we have both!! I could see a big time CEO being placed by Cathie and then she might even buy more...
Monday last week) Iovance Biotherapeutics price target lowered to $38 from $51 at Oppenheimer 07:43 IOVA Oppenheimer analyst Mark Breidenbach lowered the firm's price target on Iovance Biotherapeutics to $38 from $51 and keeps an Outperform rating on the shares. The analyst acknowledges that last week's "bombshell" announcement of CEO Maria Fardis' resignation, a day after negative feedback from the FDA, came as a shock to investors-sending shares tumbling to a 52-week low. While Breidenbach remains confident in the clinical potential of TIL therapy, he believes the CEO's departure adds material risk with respect to product commercialization. Given lifileucel's strong clinical data, Breidenbach still thinks that the CMC-related impasse with the FDA will be resolved, but has no basis for confidence in new filing timelines guided by management.
The Fools- Shares of Iovance Biotherapeutics (NASDAQ:IOVA) have been on a roller-coaster ride over the past few days. That's likely because investors don't know what to make of press releases that don't quite jibe with a big disclosure the company recently made regarding CEO Maria Fardis. On May 18, Fardis notified the company she would be resigning "to pursue other opportunities." That's a little hard to swallow because the company recently reported highly successful clinical trial results. What do you mean Cathie wants me out? Why Iovance Biotherapeutics stock fell Iovance hasn't elaborated on the other opportunities Fardis will pursue, but they probably don't involve drug development. And on the same day we learned of her departure, we also learned that Iovance's upcoming new drug application for lifileucel will be delayed until the first half of 2022. The lifileucel program will be delayed because the FDA recently made a second request for additional data regarding potency assays, which are a series of tests that prove the company can consistently manufacture the product in question. This was always going to be tough because each patient's batch of lifileucel is made from cells harvested from that patient's own tumor. Iovance stock has been extra volatile because it looks like the company's management team isn't up to the challenge it's facing. Those who follow the company had been expecting an application for lifileucel to reach the FDA in 2020, but in October, the FDA made its first request for additional data regarding potency assays. Apparently, the company's response did not satisfy the regulator. Putting together an application package for the FDA is a daunting task, but Iovance has collected more than enough capital from investors over the years to hire experts who can do the job without committing a series of unforced errors. That context suggests that Fardis was forced out of her position by a disappointed board of directors.-!!!!!!! Why the stock bounced back the next day<---- Iovance Biotherapeutics is a clinical-stage company now, but it probably shouldn't be. The company's lead candidate, lifileucel, has already produced sufficient evidence of efficacy as a treatment for advanced-stage melanoma. In addition to impressive response rate data as a monotherapy that excited investors in 2019, combining lifileucel with an already-approved immunotherapy looks extremely promising. On May 19, Iovance stock rebounded after the company revealed data from a study in which lifileucel was administered to advanced-stage melanoma patients in combination with Merck's (NYSE:MRK) immunotherapy Keytruda. The combination shrank tumors for 86% of participants. Keytruda is one of several PD-1 inhibitors that help immune systems fight cancer by limiting tumor cells' ability to block the immune system from attacking them. These treatments can be highly effective, but they don't work as often as we'd like them to. On its own, Keytruda only shrinks tumors for around one-third of treatment-naive melanoma patients who try it. Based on the data so far, it appears that adding lifileucel to the treatment regimen could more than double that response rate. Still not enough? While it looks like Fardis is being forced out by Iovance's board of directors, there's also a chance she's jumping from a ship that outside investors don't realize is sinking. Iovance Biotherapeutics has produced impressive results with its personalized cell-based approach, but simpler cancer treatments could make Iovance's lead candidate obsolete before investors can realize a return. For example, Bristol Myers Squibb (NYSE:BMY) recently announced success with an anti-LAG-3 antibody called relatlimab. This isn't a cell-based treatment, but it might solve some of the same problems lifileucel addresses without lifileucel's extra-complicated manufacturing process. Bristol Myers Squibb said that combining relatlimab with Opdivo, the company's PD-1 inhibitor, significantly reduced melanoma patients' risk of disease progression compared to treatment with Opdivo on its own. A majority of patients treated with relatlimab plus Opdivo went 10.1 months or longer without their cancer worsening compared to just 4.6 months for those given Opdovo monotherapy. ??? A lot to chew on. I would say that having a cancer not get worse for 10 months is not the same as Shrinking Cancers... So I'm on the side of IOVA and wonder if Merck might buy this co. And I wonder if we get a big fancy pants CEO with some street cred..... Or is this a sinking ship.. Cathie says NO!
FUNKO- When Van? Panini America, Funko announces Funko Pop! Trading Card line FNKO Panini America and Funko announced a new Pop! product line, Funko Pop! Trading Card that will extend across multiple sports later this year. The initial series will feature six NBA players and six NFL players and will hit retail shelves in time for the holiday shopping season. The introduction of Funko Pop! Trading Card will incorporate Panini's globally popular Prizm trading card brand for both the NBA and NFL. Similar to the very popular Pop! Albums and Pop! Comic Covers, Pop! Trading Card will feature the Panini Prizm trading card art packaged together in a protective case that can be hung on a wall. The Pop! Vinyl figure will replicate the poses from the player imagery from their respective Prizm trading cards.
Just looking at FNKO chart Van I'd say $24.50. Not a bottom per sey but this stock is a value stk anyway....
100% on board with this one. Good find Stoney. In the early stages of cancer, the immune system tries to fight cancer by mobilizing special immune cells known as lymphocytes to attack the tumor. Lymphocytes with the capacity to recognize and attack the tumor traffic to, and infiltrate into the tumor. These cells are known as tumor infiltrating lymphocytes (TIL). However, the anti-tumor effect of the TIL is usually short-lived because cancer cells adapt and employ mechanisms to evade detection by TIL, and suppress the anti-tumor immune response through the release of various anti-inflammatory factors into the local environment. Iovance TIL technology is designed to address the manifold obstacles that attenuate the natural anti-tumor immune response. TIL are extracted from the patient and expanded to billions in number by stimulating them ex vivo (in tissue culture) with IL-2. The amplification process eliminates the immune-suppressive environment created by the tumor which is so effective at neutralizing the natural anti-tumor immune response. This same culture environment optimizes the replication and activation of aggressive anti-tumor TIL. Once sufficient numbers of cells with the appropriate anti-tumor potential have been cultured, they are then re-administered back into the patient where they have been shown to mediate impressive anti-tumor responses with strong durability after a one-time administration. In Phase 2 clinical studies in patients with PD-1 naïve metastatic melanoma performed by Steven A. Rosenberg, MD, chief of surgery at the National Cancer Institute (NCI), TIL therapy demonstrated robust efficacy with objective response rates of 56% and complete response rates of 24%. They're building a place in Philly to make (replicate) these cells Stoney! They know damn well it works! It's not just one type of cancer either. I've been digging. The TAM on this is worth... god only knows how much. Cathie is right. The FDA is just covering its bases on that request, that's my guess. BUY BUY BUY!
To me racing and trading go n hand n' hand. Castronevis just won the Indy 500 after competing only in IMSA sports cars racing after being demoted due to his age and future talent. Once you know your craft - you be patient and wait for your chances (opportunities). There are so many similarities in high risk 'things'.
XPeng deliveries up 483% Y/Y on strong demand, up 10% M/M Jun. 01, 2021 4:39 AM ETXPeng Inc. (XPEV)XPeng Inc. (XPEV) XPeng(NYSE:XPEV)delivered a total of 5,686 Smart EVs in May 2021, representing a 483% increase year-over-year, and a 10%increase over last month. The May deliveries consisted of 3,797 P7s, the Company’s sports smart sedan, and 1,889 G3s, its smart compact SUV. As of May 31, 2021, year-to-date total deliveries reached 24,173 units, representing a 427% increase year-over-year. The number of P7s delivered in May reached a record high of 3,797, demonstrating the strong customer appeal of market-leading smart features. Launched in January this year, XPILOT 3.0 and its Navigation Guided Pilot highway solutions have achieved a strong set of customer utilization rates. Additionally, these solutions enable the Company to generate incremental revenues from its proprietary XPILOT software. The launch of the P7 Wing edition, and the lithium iron phosphate battery-powered G3 and P7 also contributed to the strong delivery results to date. The P7 is the best looking of the Chinese E cars.
Going with Vtech's racing analogy. Here is how maybe racing and investing is different. If I am in a race say the Gummybear 500 ..... (Oh snap that's good tm* stoney & van) and I am driving a Renault, a slow French car, in fact I am driving a Renault Le' Car... which I'm sure none of you remember. My family had one. I crashed One. They do not hold up well. But I'm driving a slow and awkward Renault Le Car with the fabric top open and someone fancy enters the race... Italian guy, Formica Famillia & he too is driving a Renault but a much faster, larger electric Renault speed/super car. The fact that a better Renault has entered the race should not affect my slow beat Up Le Car.. but it DOES SUDDENLY I AM ELEVATED ELEVEN SPOTS!!! Withing the next month or so THE EUROPEAN POWERHOUSE KLARIAN IS COMING. Klarian has a valuation that will knock your socks off-- from memory $33 billion? This is all from memory, I may have the name of the Co slightly wrong. They have an EXCELLENT CEO, one of the smartest guys I have ever listened to. This IPO should rip! Klarian does Buy Now Pay Later<------------- This IPO will " re value the whole sector " I promise you that. THEREFORE BUY AFRM IMMEDIATELY EVERYONE!!!!- The Le' car of Buy Now Pay later.